CEREVEL THERAPEUTICS
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinsonโs disease and substance use disorder.
CEREVEL THERAPEUTICS
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2018-10-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.cerevel.com
Total Employee:
251+
Status:
Active
Total Funding:
1.45 B USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Font Awesome Domain Not Resolving Nginx
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
Arkuda Therapeutics
Arkuda Therapeutics is a pharmaceutical company.
Cerebral Therapeutics
Cerebral Therapeutics is a clinical-stage pharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
Delix Therapeutics
Delix Therapeutics focuses on harnessing the power of psychoplastogens novel neuroplasticity-promoting therapeutic.
IMPACT Therapeutics
IMPACT Therapeutics is a China based Company.
Nuvation Bio
Nuvation Bio is a biopharmaceutical company.
ORIC Pharmaceuticals
ORIC Pharmaceuticals operates as a biopharmaceutical company.
Trilogy Therapeutics
Trilogy Therapeutics is a Biopharmaceutical company
Zentera Therapeutics
Zentera Therapeutics is a biopharmaceutical company.
Zomedica
Zomedica is a veterinary pharmaceutical company.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Novaquest Capital Management
Novaquest Capital Management investment in Post-IPO Equity - Cerevel Therapeutics
Bain Capital
Bain Capital investment in Post-IPO Equity - Cerevel Therapeutics
T. Rowe Price
T. Rowe Price investment in Post-IPO Equity - Cerevel Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Post-IPO Equity - Cerevel Therapeutics
Boxer Capital
Boxer Capital investment in Post-IPO Equity - Cerevel Therapeutics
Surveyor Capital
Surveyor Capital investment in Post-IPO Equity - Cerevel Therapeutics
Adage Capital Management
Adage Capital Management investment in Post-IPO Equity - Cerevel Therapeutics
Ally Bridge Group
Ally Bridge Group investment in Post-IPO Equity - Cerevel Therapeutics
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Cerevel Therapeutics
Sphera Global Healthcare Fund
Sphera Global Healthcare Fund investment in Post-IPO Equity - Cerevel Therapeutics
Key Employee Changes
Official Site Inspections
http://www.cerevel.com Semrush global rank: 2.62 M Semrush visits lastest month: 6.61 K
- Host name: 159.180.132.176
- IP address: 159.180.132.176
- Location: North Chicago United States
- Latitude: 42.325
- Longitude: -87.8561
- Metro Code: 602
- Timezone: America/Chicago
- Postal: 60064
More informations about "Cerevel Therapeutics"
About Cerevel - Cerevel Therapeutics
Transforming what is possible in neuroscience Founded in late 2018 through a partnership with Pfizer and Bain Capital, Cerevel Therapeutics is a clinical-stage biopharmaceutical company that combines a deep understanding of the โฆSee details»
Cerevel Therapeutics - Wikipedia
Cerevel's tagline mission statement is to "unravel the mysteries of the brain" to treat neurological disease. Scientifically, its approach to therapy development focuses on understanding the wiring of the brain, pursuing novel targets, and addressing specific receptor sub-types. The company has stated its approach to neurotherapy development can be viewed as: โข Development of treatment opportunities by precisely identifying and targeting the neurocircuitry tโฆSee details»
Unraveling the Mysteries of the Brain - cerevel.com
Cerevel is led by a strong management team that brings to the organization a combined track record of more than 20 prior drug approvals and launches Since its founding in 2018, Cerevel โฆSee details»
Cerevel Therapeutics - Crunchbase Company Profile
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus โฆSee details»
Bain Capital and Pfizer Create Cerevel Therapeutics, New CNS โฆ
Oct 23, 2018 Cerevel (www.cerevel.com) is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The โฆSee details»
AbbVie Completes Acquisition of Cerevel Therapeutics
Aug 1, 2024 AbbVie has acquired all outstanding Cerevel common stock for $45.00 per share. It is expected that Cerevel's common stock will cease to trade on the NASDAQ stock exchange โฆSee details»
AbbVie Completes Acquisition of Cerevel Therapeutics - PR โฆ
Aug 1, 2024 Cerevel's pipeline is highly complementary to AbbVie's existing neuroscience portfolio and the completion of the acquisition is an important step forward to delivering new โฆSee details»
AbbVie to Acquire Cerevel Therapeutics in Transformative โฆ
Dec 6, 2023 Information regarding Cerevel's directors and executive officers is set forth in Cerevel's proxy statement on Schedule 14A for its 2023 Annual Meeting of Stockholders, โฆSee details»
R&D - Cerevel Therapeutics
13 rows Striving to develop new therapies for neuroscience diseases We are focused on providing improved treatments for devastating and life-threatening neuroscience diseases that โฆSee details»
Cerevel Company Profile - Office Locations, Competitors ... - Craft
Aug 1, 2024 Cerevel Therapeutics is a biopharmaceutical company focused on developing therapies to treat disorders of the central nervous system (CNS). The company has a portfolio โฆSee details»
Cerevel Therapeutics Announces Updates to its Board of Directors
CAMBRIDGE, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience โฆSee details»
AbbVie Completes Acquisition of Cerevel Therapeutics - Yahoo โฆ
Aug 1, 2024 Cerevel's pipeline is highly complementary to AbbVie's existing neuroscience portfolio and the completion of the acquisition is an important step forward to delivering new โฆSee details»
AbbVie to Acquire Cerevel Therapeutics in Transformative โฆ
Dec 6, 2023 AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) today announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and โฆSee details»
AbbVie to Acquire Cerevel Therapeutics in Transformative โฆ
Dec 6, 2023 Information regarding Cerevel's directors and executive officers is set forth in Cerevel's proxy statement on Schedule 14A for its 2023 Annual Meeting of Stockholders, โฆSee details»
Cerevel Therapeutics Announces Third Quarter 2020 Financial โฆ
Nov 16, 2020 The increase in research and development expense was primarily due to higher program costs related to advancing our pipeline and increased personnel costs as we grew โฆSee details»
Transforming the Possible in Neuroscience - Cerevel Therapeutics
Information communicated at this meeting are strictly confidential and should not be discussed outside your organization. The reader shall not rely upon any statement, representation or โฆSee details»
Cerevel Therapeutics Reports Fourth Quarter and Full Year 2022 ...
Feb 22, 2023 Cerevel is conducting two adequately-powered placebo-controlled Phase 2 trials, known as EMPOWER-1 and EMPOWER-2. Enrollment for these trials is on track and data for โฆSee details»
AbbVie swoops on Pfizer spin-out Cerevel with $8.7bn offer
5 days ago Cerevelโs clinical pipeline also includes darigabat, an ฮฑ2/3/5-selective GABAA receptor PAM currently under in a phase 2a proof-of-concept trial in epilepsy and panic โฆSee details»
Newsroom - Cerevel Therapeutics
In the news The latest news and resources from Cerevel Therapeutics. Media inquiries Press Releases and Featured News Presentations & Events Media Kit Cerevel Therapeutics is โฆSee details»